KRAS and non-small cell lung carcinoma: Moreover, considering alemtuzumab, an anti-PD-L1 immunotherapy for NSCLC patients, it was shown that in the group of non-oncogene-addicted mNSCLC patients, mutations in STK11 and KEAP1 are associated with a poor prognosis, and exploratory subgroup analysis of clinical trials suggested that they are associated with lower immune checkpoint inhibitor (ICI) efficacy, especially in KRAS-mutated tumors [170–172].